Abstract:Highly active antiretroviral therapy (HAART) is very effective in suppressing human immunodeficiency virus type 1 (HIV‑1) replication. However, the treatment is required to be administered for the remainder of an individual's lifetime due to latent HIV‑1 reservoirs. The 'shock‑and‑kill' strategy, which involves using agents to reactivate latent HIV‑1 and subsequently killing latently infected cells in the presence of HAART, was recently proposed. Unfortunately, no agents have currently demonstrated an ability to reactivate latent HIV‑1 in vivo in the absence of toxicity. Therefore, the identification of novel latency activators is required. In order to identify a potential novel agent, the present study investigated the effect of quercetin on latent HIV‑1 reactivation using an established model of HIV‑1 latency. As a marker for reactivation of HIV‑1 in C11 Jurkat cells, the expression of green fluorescent protein, controlled by HIV‑1 long terminal repeat, was observed by fluorescence microscopy. The results of the present study demonstrated that quercetin effectively reactivated latent HIV‑1 gene expression alone, and led to synergistic reactivation when combined with prostratin or valproic acid. In addition, the present study provides evidence that quercetin may reactivate HIV‑1 expression by inducing nuclear factor‑κB nuclear translocation, and that the toxicity of quercetin is lower when compared with various additional activators of HIV‑1. Combined, the results of the present study indicate that quercetin may be an effective agent to disrupt HIV‑1 latency and may be useful in future eradication strategies.

BET inhibitors RVX-208 and PFI-1 reactivate HIV-1 from latency

Reactivation of HIV-1 from Latency by an Ingenol Derivative from Euphorbia Kansui

Development of an Attenuated Tat Protein as a Highly-effective Agent to Specifically Activate HIV-1 Latency

Dilazep Synergistically Reactivates Latent HIV-1 in Latently Infected Cells.

The BET inhibitor OTX015 reactivates latent HIV-1 through P-TEFb

Dual effects of the novel ingenol derivatives on the acute and latent HIV-1 infections

CBX4 Contributes to HIV-1 Latency by Forming Phase-Separated Nuclear Bodies and SUMOylating EZH2.

Bromodomain and Extra-Terminal Inhibitor BMS-986158 Reverses Latent HIV-1 Infection In Vitro and Ex Vivo by Increasing CDK9 Phosphorylation and Recruitment

The Bromodomain And Extraterminal Domain Inhibitor Bromosporine Synergistically Reactivates Latent Hiv-1 In Latently Infected Cells

BET Degraders Reveal BRD4 Disruption of 7SK and P-TEFb is Critical for Effective Reactivation of Latent HIV in CD4+ T-cells

A First-in-Class Dual Degrader of Bcl-2/Bcl-xL Reverses HIV Latency and Eliminates Ex Vivo Reservoirs

Progress and Challenges in the Use of Latent HIV-1 Reactivating Agents

Release of P-TEFb from the Super Elongation Complex promotes HIV-1 latency reversal

Quantitative proteomics of the CDK9 interactome reveals a novel function of the HSP90-CDC37-P-TEFb complex for BETi-induced HIV-1 latency reactivation

Quercetin Synergistically Reactivates Human Immunodeficiency Virus Type 1 Latency by Activating Nuclear Factor‑κb.

KDM5A/B promotes HIV-1 latency and KDM5 inhibitors promote HIV-1 lytic reactivation

A Natural Product From Polygonum Cuspidatum Sieb. Et Zucc. Promotes Tat-Dependent Hiv Latency Reversal Through Triggering P-Tefb'S Release From 7sk Snrnp

In vivo activation of latent HIV with a synthetic bryostatin analog effects both latent cell "kick" and "kill" in strategy for virus eradication

PEBP 1 suppresses HIV transcription and induces latency by inactivating MAPK / NF ‐κB signaling

Effective and targeted latency reversal in CD4+ T cells from individuals on long term combined antiretroviral therapy initiated during chronic HIV-1 infection

Ripretinib inhibits HIV-1 transcription through modulation of PI3K-AKT-mTOR